Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
The European Journal of Heart Failure continues to thrive and the 2017 impact factor, released in 2018, was 10.683.
Professor Marco Metra (University of Brescia, Brescia, Italy), Editor-in-Chief, is proud of its progress, saying, “In 2017, the European Journal of Heart Failure was ranked sixth out of all journals specialised in the cardiac and cardiovascular system.
This is due to the high quality of submissions, the extreme commitment of reviewers and associate editors who select the highest priority publications and, last but not least, our dedicated readership who are keen to learn about the latest advancements. The most highly cited article in the European Journal of Heart Failure, and one of the most accessed papers, is by far the 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure—it is encouraging that our recommendations, the best referral of current knowledge, are so broadly read and disseminated among other publications.”
Prof. Metra describes how HFA position statements are also widely cited. In fact, the most highly cited paper from 2018 was the HFA position statement on type 2 diabetes mellitus and heart failure, with position papers on the role of cardiopulmonary exercise testing in clinical stratification in heart failure, on heart and brain interactions, and on right heart dysfunction in heart failure with preserved ejection fraction also appearing among the most quoted articles.
Publishing high-quality research articles remains a key aim of the European Journal of Heart Failure. One of the most highly cited research articles from 2018 was an individual patient data meta-analysis on the effect of ferric carboxymaltose on outcomes in irondeficient heart failure patients. Other widely cited articles include an analysis of CHARM that studied the effects of candesartan in patients with mid-range ejection fraction, an assessment of the prognostic value of the 2015 ESC classification of pulmonary hypertension and a long-term comparison of the prognostic accuracy of different multiparametric approaches for risk stratification in patients with reduced ejection fraction.
This morning, the year’s best papers on biomarkers, imaging, medical treatment and devices will be described by expert speakers in a special session chaired by Prof. Metra and by Professors Stefan Anker and Stephan von Haehling, Editor-in-Chief and Deputy Editor (Clinical), respectively, of ESC Heart Failure, the open-access sister journal of the European Journal of Heart Failure.
‘The year’s best papers on heart failure’
Sunday, 11:00 – 12:30; Lambrakis
Our mission: To reduce the burden of cardiovascular disease.
© 2020 European Society of Cardiology. All rights reserved.